Rare MIS-C cases in pediatric patients vaccinated with COVID-19

A new observational study of children and adolescents at least once COVID-19 (new coronavirus infection) Vaccination has rarely reported cases of multisystem inflammatory syndrome (MIS-C), and the reporting rate for MIS-C with no evidence of SARS-CoV-2 infection is 1 million vaccinated at this age. It turned out that there were 0.3 cases per person. group.

According to a study published in The Lancet Child & Adolescent Health Journal, MIS-C case rates for vaccinated children and adolescents aged 12 to 20 years in the United States were previously found in unvaccinated individuals aged 12 to 20 years. It turned out to be significantly lower than the estimates published in. Years of COVID-19 infection from April to June 2020.

Inflammatory polyphyly syndrome in children is a rare condition associated with COVID-19, first recognized in April 2020. This is an immune hyperreactivity that is thought to occur approximately 2-6 weeks after COVID-19 infection in children and adolescents. Symptoms include rash, fever, red eye, and gastrointestinal symptoms, which can lead to multiple organ failure.

It is necessary to report possible cases after vaccination under the emergency permission of COVID-19 vaccine, which allows researchers in the current study to report during the first 9 months of COVID-19 vaccination. We are now assessing reported MIS-C cases in children and adolescents aged 12 to 20 years. Deployment in the United States.

A team of specialists and epidemiologists investigated 47 reports of potential MIS-C diseases reported between December 14, 2020 and August 31, 2021.

Of these 47 reports, 21 meet the Centers for Disease Control and Prevention (CDC) MIS-C standards. Case report rates were calculated using CDC national vaccine surveillance data on the number of individuals aged 12 to 20 years.

Of the 21 cases of MIS-C, 15 had evidence of past or recent infection with the COVID-19 virus.

Over 21 million children and adolescents between the ages of 12 and 20 have been vaccinated with one or more COVID-19 vaccines, with one report per million individuals vaccinated in this age group. ..

Importantly, the researchers emphasized that in these rare cases it was not possible to determine whether vaccination contributed to the disease of MIS-C.

Given that MIS-C was first identified during a pandemic, baseline rates for unidentified pediatric and adolescent inflammatory diseases have not previously existed. The team noted that some identified cases may have other unrecognized inflammatory conditions that occurred after vaccination.

Of the 15 pediatric patients previously infected with COVID-19, 3 were diagnosed with MIS-C outside the usual 2-6 week period.

Of the 21 hospitalized, 12 were admitted to the intensive care unit. All individuals were discharged home.

In addition, all individuals with MIS-C in this study were vaccinated with the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine. At that time, it was the only COVID-19 vaccine approved in the country for use in people under the age of 18.

A total of 11 patients received 1 dose and 10 patients received 2 doses prior to the onset of illness, with median duration of administration to admission of 8 and 5 days, respectively.

Dr. Anna R. Yousaf of the Centers for Disease Control and Prevention (CDC) said clinicians and researchers were learning about MIS-C during pandemics, and the current study highlights challenges in diagnosing MIS-C. The importance of considering alternative diagnoses, and the need to monitor MIS-C diseases. “

“Our results show that cases of MIS-C after COVID-19 vaccination are rare and that unvaccinated children infected with COVID-19 are much more likely to develop MIS-C. I suggest, “Yousaf said in a statement. “COVID-19 vaccination is recommended for all people over the age of 5 in the United States for the prevention of COVID-19.”